{"created":"2023-06-19T11:23:20.378023+00:00","id":3857,"links":{},"metadata":{"_buckets":{"deposit":"04452348-bae6-47cb-a7bc-eb889b3ce961"},"_deposit":{"created_by":3,"id":"3857","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"3857"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:00003857","sets":["7","7:23"]},"author_link":["11514","11515"],"item_5_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-05-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"59","bibliographicPageStart":"51","bibliographicVolumeNumber":"1","bibliographic_titles":[{"bibliographic_title":"糖尿病レクチャー"}]}]},"item_5_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"＜point＞糖尿病における治療目標は、慢性合併症である糖尿病細小血管合併症および動脈硬化性疾患の発症を阻止し、進展を抑制することである。血糖コントロールの指標は、HbA1c、空腹時血糖値、随時血糖値、食後血糖値、グリコアルブミン、1、5-AGがあるが、それぞれの長所・短所を理解しコントロールに用いる。我が国では合併症を起こさないHbA1cレベルを6.5%未満としており、米国糖尿病学会でもA1Cレベルで7.0%以下を(HbA1cで約6.6%)目標としている。グリコヘモグロビンは国際標準化のため、近い将来HbA1cよりA1Cへ統一化される。合併症の早期発見のため、尿中アルブミンの測定や定期的な眼科受診は必須である。","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_5_description_36":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_description":"著者最終原稿版","subitem_description_type":"Other"}]},"item_5_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"text","subitem_description_type":"Other"}]},"item_5_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_5_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2185-1611","subitem_source_identifier_type":"PISSN"}]},"item_5_text_44":{"attribute_name":"ID(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"2010236016"}]},"item_5_text_54":{"attribute_name":"閲覧数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"913"}]},"item_5_text_55":{"attribute_name":"ダウンロード数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"1016"}]},"item_5_text_7":{"attribute_name":"著者 ローマ字","attribute_value_mlt":[{"subitem_text_value":"Haneda, Masakazu"},{"subitem_text_language":"en"}]},"item_5_version_type_38":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"藤田, 征弘","creatorNameLang":"ja"},{"creatorName":"フジタ, ユキヒロ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"11514","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"羽田, 勝計","creatorNameLang":"ja"},{"creatorName":"ハネダ, マサカズ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"11515","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-06"}],"displaytype":"detail","filename":"4567.pdf","filesize":[{"value":"359.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"4567.pdf","url":"https://asahikawa-med.repo.nii.ac.jp/record/3857/files/4567.pdf"},"version_id":"4357a85c-3b99-4ca2-bf15-3ba4aa5123fa"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"【新しい経口糖尿病薬療法　インクレチン薬をめぐって】 糖尿病治療の指標とは","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"【新しい経口糖尿病薬療法　インクレチン薬をめぐって】 糖尿病治療の指標とは","subitem_title_language":"ja"}]},"item_type_id":"5","owner":"3","path":["6","7","23"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2012-05-24"},"publish_date":"2012-05-24","publish_status":"0","recid":"3857","relation_version_is_last":true,"title":["【新しい経口糖尿病薬療法　インクレチン薬をめぐって】 糖尿病治療の指標とは"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2024-07-26T09:04:26.691737+00:00"}